Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

MiNK Therapeutics Q2 EPS $(1.06) Misses $(0.46) Estimate

Author: Benzinga Newsdesk | August 14, 2025 06:33am
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.46) by 132.97 percent. This is a 45.21 percent decrease over losses of $(0.73) per share from the same period last year.

Posted In: INKT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist